



Cyxone announces change of Certified Adviser to FNCA

Cyxone AB (publ), Reg. No. 559020-5471 (the "Company"), hereby announces that the Company has entered into an agreement with FNCA Sweden AB ("FNCA") regarding the service as a Certified Adviser. FNCA will be appointed Certified Adviser (CA) on 1 December 2021. Up until then, Mangold Fondkommission AB will continue to act as Certified Adviser for the Company.

Contact

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

The information was submitted for publication, through the agency of the contact person set out above, at 14.15 p.m. CET on 30 November 2021.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com